Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) - ...
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has ...
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of ...
SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research ...
(RTTNews) - Myriad Genetics, Inc. (MYGN), a genetic testing and precision medicine company, on Wednesday announced its groundbreaking study results on the Prequel Prenatal Screen with AMPLIFY ...
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...
Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...